Swiss - Delayed Quote CHF

PolyPeptide Group AG (PPGN.SW)

20.15
+0.45
+(2.28%)
At close: May 9 at 5:31:16 PM GMT+2
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
338,688
338,688
324,771
2,316
3,959
Cost of Revenue
299,422
299,422
315,730
228,987
182,426
Gross Profit
39,266
39,266
9,041
-226,671
-178,467
Operating Expense
45,261
45,261
42,919
41,700
39,494
Operating Income
-5,995
-5,995
-33,878
-268,371
-217,961
Net Non Operating Interest Income Expense
-16,963
-16,963
-7,280
-3,413
-3,095
Pretax Income
-18,145
-18,145
-58,243
7,567
59,848
Tax Provision
1,419
1,419
-6,803
-200
12,590
Net Income Common Stockholders
-19,564
-19,564
-51,440
7,767
47,258
Diluted NI Available to Com Stockholders
-19,564
-19,564
-51,440
7,767
47,258
Basic EPS
-0.59
--
-1.56
0.24
1.47
Diluted EPS
-0.59
--
-1.56
0.24
1.47
Basic Average Shares
32,980
--
32,941
32,986
32,097
Diluted Average Shares
33,000
--
32,968
33,004
32,124
Total Operating Income as Reported
-7,364
-7,364
-36,468
12,607
64,165
Total Expenses
344,683
344,683
358,649
270,687
221,920
Net Income from Continuing & Discontinued Operation
-19,564
-19,564
-51,440
7,767
47,258
Normalized Income
-18,311.37
-18,311.37
-49,153.03
7,767
47,258
Interest Income
586
586
54
9
8
Interest Expense
13,848
13,848
5,623
2,091
2,823
Net Interest Income
-16,963
-16,963
-7,280
-3,413
-3,095
EBIT
-4,297
-4,297
-52,620
9,658
62,671
EBITDA
28,417
28,417
-22,151
35,721
83,354
Reconciled Cost of Revenue
299,422
299,422
315,730
228,987
182,426
Reconciled Depreciation
32,714
32,714
30,469
26,063
20,683
Net Income from Continuing Operation Net Minority Interest
-19,564
-19,564
-51,440
7,767
47,258
Total Unusual Items Excluding Goodwill
-1,369
-1,369
-2,590
--
0
Total Unusual Items
-1,369
-1,369
-2,590
--
0
Normalized EBITDA
29,786
29,786
-19,561
35,721
83,354
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-116.37
-116.37
-303.03
0
0
12/31/2021 - 4/28/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SFZNz.XC
 
SDZ.SW Sandoz Group AG
38.03
+2.07%
 
002755.SZ Beijing Aosaikang Pharmaceutical Co., Ltd.
17.95
+1.41%
 
300723.SZ ApicHope Pharmaceutical Group Co., Ltd.
35.95
-1.53%
 
NGQ1.F Medicure Inc.
0.5350
-0.93%
 
KABRADG.BO Kabra Drugs Limited
11.08
0.00%
 
688506.SS Sichuan Biokin Pharmaceutical Co.,Ltd.
280.00
+0.61%
 
HLNl.XC
 
069620.KS Daewoong Pharmaceutical Co., Ltd
140,700.00
-1.40%
 
TRILC.IS Turk Ilac Ve Serum Sanayi Anonim Sirketi
19.49
-0.61%